Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Globe Newswire•28/10/2026•08:00 ET
0
Key Highlights
- ➤135 of 182 planned patients randomized and received Allocetra’s first injection
- ➤Phase 2b trial actively recruiting across clinical sites in United States and Europe
- ➤Topline six-month Phase 2b data expected by mid-2027
- ➤FDA granted Allocetra RMAT designation in July 2026
Expert Statements
Einat Galamidi, M.D., Chief Medical Officer of Enlivex
“We are very excited by the progress of our Phase 2b trial. Reaching more than 70% of randomization in the trial reflects strong engagement from our investigators and patients across the United States and Europe. Our team is committed to executing this study to the highest standards of quality and in accordance with our stated timelines, and we look forward to reporting topline six-month data by mid-2027.”
• 135 patients, out of a total planned 182, have been randomized and were administered the first injection of Allocetra(TM); enrollment actively ongoing at clinical sites in the United States and in Europe
• Phase 2b builds on positive three- and six-month Phase 1/2a data, which supported FDA Regenerative Medicine Advanced Therapy (RMAT) designation granted in July 2026
Get started
Create a free account to read the full story.